Elevation of receptor tyrosine kinases by small molecule AKT inhibitors in prostate cancer is mediated by Pim-1

Bo Cen, Sandeep Mahajan, Wenxue Wang, Andrew Kraft

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

The PI3K/AKT pathway is hyperactivated in prostate cancer but its effective therapeutic targeting has proven difficult. In particular, the antitumor activity of AKT inhibitors is attenuated by upregulation of receptor tyrosine kinases (RTK) through an uncharacterized feedback mechanism. In this report, we show that RNA interferencemediated silencing or pharmacologic inhibition of Pim-1 activity curtails AKT inhibitor-induced upregulation of RTKs in prostate cancer cells. Although Pim kinases have been implicated in cap-dependent translational control, we find that in the context of AKT inhibition, the expression of RTKs is controlled by Pim-1 in a cap-independent manner by controlling internal ribosome entry. Combination of Pim and AKT inhibitors resulted in synergistic inhibition of prostate tumor growth in vitro and in vivo. Together, our results show that Pim-1 mediates resistance to AKT inhibition and suggest its targeting to improve the efficacy of AKT inhibitors in anticancer therapy.

Original languageEnglish (US)
Pages (from-to)3402-3411
Number of pages10
JournalCancer Research
Volume73
Issue number11
DOIs
StatePublished - Jun 1 2013
Externally publishedYes

Fingerprint

Receptor Protein-Tyrosine Kinases
Prostatic Neoplasms
Up-Regulation
RNA Interference
Phosphatidylinositol 3-Kinases
Ribosomes
Prostate
Therapeutics
Growth
Neoplasms
In Vitro Techniques
proto-oncogene proteins pim

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Elevation of receptor tyrosine kinases by small molecule AKT inhibitors in prostate cancer is mediated by Pim-1. / Cen, Bo; Mahajan, Sandeep; Wang, Wenxue; Kraft, Andrew.

In: Cancer Research, Vol. 73, No. 11, 01.06.2013, p. 3402-3411.

Research output: Contribution to journalArticle

@article{bbcd0cc21d6b43b2a6bb55ba36585825,
title = "Elevation of receptor tyrosine kinases by small molecule AKT inhibitors in prostate cancer is mediated by Pim-1",
abstract = "The PI3K/AKT pathway is hyperactivated in prostate cancer but its effective therapeutic targeting has proven difficult. In particular, the antitumor activity of AKT inhibitors is attenuated by upregulation of receptor tyrosine kinases (RTK) through an uncharacterized feedback mechanism. In this report, we show that RNA interferencemediated silencing or pharmacologic inhibition of Pim-1 activity curtails AKT inhibitor-induced upregulation of RTKs in prostate cancer cells. Although Pim kinases have been implicated in cap-dependent translational control, we find that in the context of AKT inhibition, the expression of RTKs is controlled by Pim-1 in a cap-independent manner by controlling internal ribosome entry. Combination of Pim and AKT inhibitors resulted in synergistic inhibition of prostate tumor growth in vitro and in vivo. Together, our results show that Pim-1 mediates resistance to AKT inhibition and suggest its targeting to improve the efficacy of AKT inhibitors in anticancer therapy.",
author = "Bo Cen and Sandeep Mahajan and Wenxue Wang and Andrew Kraft",
year = "2013",
month = "6",
day = "1",
doi = "10.1158/0008-5472.CAN-12-4619",
language = "English (US)",
volume = "73",
pages = "3402--3411",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Elevation of receptor tyrosine kinases by small molecule AKT inhibitors in prostate cancer is mediated by Pim-1

AU - Cen, Bo

AU - Mahajan, Sandeep

AU - Wang, Wenxue

AU - Kraft, Andrew

PY - 2013/6/1

Y1 - 2013/6/1

N2 - The PI3K/AKT pathway is hyperactivated in prostate cancer but its effective therapeutic targeting has proven difficult. In particular, the antitumor activity of AKT inhibitors is attenuated by upregulation of receptor tyrosine kinases (RTK) through an uncharacterized feedback mechanism. In this report, we show that RNA interferencemediated silencing or pharmacologic inhibition of Pim-1 activity curtails AKT inhibitor-induced upregulation of RTKs in prostate cancer cells. Although Pim kinases have been implicated in cap-dependent translational control, we find that in the context of AKT inhibition, the expression of RTKs is controlled by Pim-1 in a cap-independent manner by controlling internal ribosome entry. Combination of Pim and AKT inhibitors resulted in synergistic inhibition of prostate tumor growth in vitro and in vivo. Together, our results show that Pim-1 mediates resistance to AKT inhibition and suggest its targeting to improve the efficacy of AKT inhibitors in anticancer therapy.

AB - The PI3K/AKT pathway is hyperactivated in prostate cancer but its effective therapeutic targeting has proven difficult. In particular, the antitumor activity of AKT inhibitors is attenuated by upregulation of receptor tyrosine kinases (RTK) through an uncharacterized feedback mechanism. In this report, we show that RNA interferencemediated silencing or pharmacologic inhibition of Pim-1 activity curtails AKT inhibitor-induced upregulation of RTKs in prostate cancer cells. Although Pim kinases have been implicated in cap-dependent translational control, we find that in the context of AKT inhibition, the expression of RTKs is controlled by Pim-1 in a cap-independent manner by controlling internal ribosome entry. Combination of Pim and AKT inhibitors resulted in synergistic inhibition of prostate tumor growth in vitro and in vivo. Together, our results show that Pim-1 mediates resistance to AKT inhibition and suggest its targeting to improve the efficacy of AKT inhibitors in anticancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=84878572236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878572236&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-12-4619

DO - 10.1158/0008-5472.CAN-12-4619

M3 - Article

C2 - 23585456

AN - SCOPUS:84878572236

VL - 73

SP - 3402

EP - 3411

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 11

ER -